FDA Issues UDI Final Rule, Removes Direct Marking Requirement For Implants
This article was originally published in The Gray Sheet
Executive Summary
The long-awaited unique device identifier final rule is intended to help FDA, device companies and health care providers track medical devices. The rule addresses many of industry’s concerns with FDA’s initial proposal and was met with general support by companies.
You may also be interested in...
Direct-Marking UDI Draft Lays Out Tips, Timelines For Reprocessed Devices
The agency issued draft guidance document on direct marking requirements for unique device identifiers, seeking guidance on the definition of "reprocessing" and laying out timelines.
Shuren Highlights CDRH Actions To Ease Trial Burdens On Capitol Hill
CDRH Director Jeffrey Shuren participated in the first roundtable of a newly launched House Energy and Commerce Committee initiative to accelerate drug and device development. He emphasized the device center’s recent proposals to minimize pre-market data collection with postmarket controls, and supported the promise of clinical trial networks.
AdvaMed Looks To Leverage U.S. Regs For Global Convergence
The trade group, under its new board chairman José Almeida, plans to push for the relatively new U.S. unique device identifier and Sunshine Act regulations to be the basis of globally harmonized mandates.